The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays

Abstract

Backgroundc-MET is an oncogene protein that plays important role in gastric carcinogenesis and has been introduced as a prognostic marker and potential therapeutic target. The aim of this study was to evaluate the frequency of c-MET overexpression and its relationship with clinicopathological variables in gastric cancer of Iranian population using tissue microarray.MethodsIn a cross sectional study, representative paraffin blocks of 130 patients with gastric carcinoma treated by curative gastrectomy during a 2 years period of 2008–2009 in two university hospitals in Tehran-Iran were collected in tissue microarray and c-MET expression was studied by immunohistochemical staining.ResultsFinally 124 cases were evaluated, constituted of 99 male and 25 female with the average age of 61.5 years. In 71% (88/124) of tumors, c-MET high expression was found. c-MET high expression was more associated with intestinal than diffuse tumor type (P = 0.04), deeper tumor invasion, pT3 and pT4 versus pT1 and pT2 (P = 0.014), neural invasion (P = 0.002) and advanced TNM staging, stage 3 and 4 versus stage 1 and2 (P = 0.044). The c-MET high expression was not associated with age, sex, tumor location, differentiation grade and distant metastasis, but relative associations with lymph node metastasis (P = 0.065) and vascular invasion (P = 0.078) were observed.Conclusionsc-MET oncogene protein was frequently overexpressed in Iranian gastric carcinomas and it was related to clinicopathological characteristics such as tumor type, depth of invasion, neural invasion and TNM staging. It can also support the idea that c-MET is a potential marker for target therapy in Iranian gastric cancer.Virtual slidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/9744598757151429

Expression of Neuronal Markers, NFP and GFAP, in Malignant Astrocytoma

“…The immunohistochemical staining of the GFAB and NFP antigen was performed on sections prepared from formalin-fixed paraffin-embedded tissues (FFPE) as described previously (Madjd et al, 2011;Sotoudeh et al, 2012;Gheytanchi et al, 2014;Keymoosi et al, 2014). Polyclonal rabit anti-human glial fibrillary acidic protein (GFAP) (Code No.Z0334, Dako, Denmark); and monoclonal mouse anti-human neurofilament NE14 (anti-NF, clone NE14, BioGenex, The Netherlands), which reacts with the 200-kilodalton component of this protein (NFP), was used as a primary antibodies.…”

Clinical significance of MET in gastric cancer

“…Moreover, MET overexpression was more frequently detected in dysplasia and precancerous gastric lesions than in intestinal metaplasia [21] . MET overexpression has frequently been found in intestinal type or differentiated type cancers [12,14,22,23] , although one study reported a correlation with diffuse type [13] . Retterspitz reported that MET was overexpressed in 51% (45 of 88) of diffuse type tumors [24] .…”

“…Retterspitz reported that MET was overexpressed in 51% (45 of 88) of diffuse type tumors [24] . MET overexpression has been significantly associated with tumor invasion depth [12,13,23] , lymph-node metastasis [12,13,19,20,25,26] , distant metastasis [12,13,25] , tumor stage [12,20,23,26] , and recurrence [14] , although several studies found no relation to any clinicopathological factors [24,27,28] . MET overexpression correlated with liver metastasis only in stage Ⅳ disease [29] .…”

Expression of EMSY, a Novel BRCA2-link Protein, is Associated with Lymph Node Metastasis and Increased Tumor Size in Breast Carcinomas

“…Breast cancer tissue microarrays were prepared as described previously (Kononen et al, 1998;Mehrazma et al, 2012;Sotoudeh et al, 2012;Mohsenzadegan et al, 2013). All cases were reviewed and the tumor area was marked on their H&E stained slides.…”